NASDAQ:PRTK - Paratek Pharmaceuticals Stock Price, Price Target & More

Paratek Pharmaceuticals trades on the NASDAQ under the ticker symbol "PRTK."

Paratek Pharmaceuticals Inc (NASDAQ:PRTK) issued its quarterly earnings results on Wednesday, May, 9th. The specialty pharmaceutical company reported ($0.91) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.94) by $0.03. The specialty pharmaceutical company had revenue of $0.01 million for the quarter, compared to analyst estimates of $0.02 million. Paratek Pharmaceuticals had a negative return on equity of 87.29% and a negative net margin of 707.08%. View Paratek Pharmaceuticals' Earnings History.

7 equities research analysts have issued 1 year price objectives for Paratek Pharmaceuticals' stock. Their predictions range from $36.00 to $55.00. On average, they anticipate Paratek Pharmaceuticals' share price to reach $45.00 in the next year. This suggests a possible upside of 324.5% from the stock's current price. View Analyst Ratings for Paratek Pharmaceuticals.

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Paratek Pharmaceuticals in the last year. There are currently 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy."

Some companies that are related to Paratek Pharmaceuticals include Myovant Sciences (MYOV), Radius Health (RDUS), Uniqure (QURE), Eagle Pharmaceuticals (EGRX), Alder Biopharmaceuticals (ALDR), Zai Lab (ZLAB), Reata Pharmaceuticals (RETA), Retrophin (RTRX), Endocyte (ECYT), Athenex (ATNX), Tricida (TCDA), Esperion Therapeutics (ESPR), Wave Life Sciences (WVE), Intra-Cellular Therapies (ITCI) and Vanda Pharmaceuticals (VNDA).

News articles about PRTK stock have trended somewhat positive on Monday, Accern Sentiment Analysis reports. The research firm rates the sentiment of press coverage by monitoring more than twenty million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Paratek Pharmaceuticals earned a daily sentiment score of 0.21 on Accern's scale. They also assigned press coverage about the specialty pharmaceutical company an impact score of 45.61 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company's share price in the next several days.

Shares of PRTK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of PRTK stock can currently be purchased for approximately $10.60.

Paratek Pharmaceuticals has a market capitalization of $334.92 million and generates $12.62 million in revenue each year. The specialty pharmaceutical company earns $-89,060,000.00 in net income (profit) each year or ($3.30) on an earnings per share basis. Paratek Pharmaceuticals employs 83 workers across the globe.

Paratek Pharmaceuticals' mailing address is 75 PARK PLAZA, BOSTON MA, 02116. The specialty pharmaceutical company can be reached via phone at 617-807-6600 or via email at [email protected]